Novartis Blocks Ranbaxy From Launching Galvus Copies
This article was originally published in PharmAsia News
Executive Summary
In the latest of a series of injunctions, the Swiss drug maker has blocked India’s Ranbaxy from launching copies of its hit anti-diabetes brand Galvus.